Related Experiment Video
Updated: Jan 14, 2026

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
Published on: November 2, 2020
How participants in cancer trials are chosen: ethics and conflicting interests
1Cancer Research UK, University of Manchester, Department of Medical Oncology, Christie Hospital, Withington, Manchester M20 4BX, UK. Gordon.Jayson@christie-tr.nwest.nhs.uk
Abstract:
The development of new drugs for cancer is extremely complex and expensive, and poses ethical problems. In this article we will review issues in clinical trials for cancer drugs that will cast new light on the doctor-patient relationship and their interaction with industry, the health service, academic and administrative organizations. We show that the Declaration of Helsinki cannot be applied to cancer trials as it is currently written, that patients do not and perhaps cannot give fully informed consent to participate, and that the results of clinical trials do not translate into daily practice in a way that patients might expect.
Related Concept Videos
07:52In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity
08:54In vivo Application of the REMOTE-control System for the Manipulation of Endogenous Gene Expression
11:53A Protocol for Multiple Gene Knockout in Mouse Small Intestinal Organoids Using a CRISPR-concatemer
10:19Generation of Genetically Modified Mice through the Microinjection of Oocytes
13:10DNA Vector-based RNA Interference to Study Gene Function in Cancer
10:58Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

